{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T15:01:46Z","timestamp":1784127706878,"version":"3.55.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T00:00:00Z","timestamp":1720483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T00:00:00Z","timestamp":1720483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Capital Medical University Undergraduate Science and Technology Innovation Fund","award":["XSKY2023255"],"award-info":[{"award-number":["XSKY2023255"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Cholangiocarcinoma (CCA), characterized by high heterogeneity and extreme malignancy, has a poor prognosis. Doublecortin-like kinase 1 (DCLK1) promotes a variety of malignant cancers in their progression. Targeting DCLK1 or its associated regulatory pathways can prevent the generation and deterioration of several malignancies. However, the role of DCLK1 in CCA progression and its molecular mechanisms remain unknown. Therefore, we aimed to investigate whether and how DCLK1 contributes to CCA progression.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The expression of DCLK1 in CCA patients was detected using Immunohistochemistry (IHC). We established DCLK1 knockout and DCLK1 overexpression cell lines for Colony Formation Assay and Transwell experiments to explore the tumor-promoting role of DCLK1. RT-PCR, Western blot and multiple fluorescent staining were used to assess the association between DCLK1 and epithelial\u2013mesenchymal transition (EMT) markers. RNA sequencing and bioinformatics analysis were performed to identify the underlying mechanisms by which DCLK1 regulates CCA progression and the EMT program.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>DCLK1 was overexpressed in CCA tissues and was associated with poor prognosis. DCLK1 overexpression facilitated CCA cell invasion, migration, and proliferation, whereas DCLK1 knockdown reversed the malignant tendencies of CCA cells, which had been confirmed both in vivo and in vitro. Furthermore, we demonstrated that DCLK1 was substantially linked to the advancement of the EMT program, which included the overexpression of mesenchymal markers and the downregulation of epithelial markers. For the underlying mechanism, we proposed that the PI3K\/AKT\/mTOR pathway is the key process for the role of DCLK1 in tumor progression and the occurrence of the EMT program. When administered with LY294002, an inhibitor of the PI3K\/AKT\/mTOR pathway, the tumor\u2019s ability to proliferate, migrate, and invade was greatly suppressed, and the EMT process was generally reversed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>DCLK1 facilitates the malignant biological behavior of CCA cells through the PI3K\/AKT\/mTOR pathway. In individuals with cholangiocarcinoma who express DCLK1 at high levels, inhibitors of the PI3K\/AKT\/mTOR signaling pathway may be an effective therapeutic approach. <\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00432-024-05875-3","type":"journal-article","created":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T10:09:57Z","timestamp":1720519797000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Targeting the PI3K\/AKT\/mTOR pathway offer a promising therapeutic strategy for cholangiocarcinoma patients with high doublecortin-like kinase 1 expression"],"prefix":"10.1007","volume":"150","author":[{"given":"Ziwei","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunting","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeru","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangyu","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donglei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,9]]},"reference":[{"issue":"20","key":"5875_CR1","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","volume":"380","author":"F Andr\u00e9","year":"2019","unstructured":"Andr\u00e9 F et al (2019) Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med 380(20):1929\u20131940","journal-title":"N Engl J Med"},{"issue":"11","key":"5875_CR2","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.4161\/epi.22191","volume":"7","author":"K Andresen","year":"2012","unstructured":"Andresen K et al (2012) Novel target genes and a valid biomarker panel identified for cholangiocarcinoma. Epigenetics 7(11):1249\u20131257","journal-title":"Epigenetics"},{"issue":"5","key":"5875_CR3","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1002\/hep.27707","volume":"61","author":"K Andresen","year":"2015","unstructured":"Andresen K et al (2015) Four DNA methylation biomarkers in biliary brush samples accurately identify the presence of cholangiocarcinoma. Hepatology 61(5):1651\u20131659","journal-title":"Hepatology"},{"issue":"9","key":"5875_CR4","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","volume":"17","author":"JM Banales","year":"2020","unstructured":"Banales JM et al (2020) Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol 17(9):557\u2013588","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"12","key":"5875_CR5","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.3390\/cancers12123801","volume":"12","author":"Z Cao","year":"2020","unstructured":"Cao Z et al (2020) Tuft and cancer stem cell marker DCLK1: a new target to enhance anti-tumor immunity in the tumor microenvironment. Cancers 12(12):3801","journal-title":"Cancers"},{"key":"5875_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216437","volume":"578","author":"S Dogra","year":"2023","unstructured":"Dogra S et al (2023) Targeting doublecortin-like kinase 1 reveals a novel strategy to circumvent chemoresistance and metastasis in ovarian cancer. Cancer Lett 578:216437","journal-title":"Cancer Lett"},{"issue":"5","key":"5875_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2022.100737","volume":"27","author":"A Elvevi","year":"2022","unstructured":"Elvevi A et al (2022) Clinical treatment of cholangiocarcinoma: an updated comprehensive review. Ann Hepatol 27(5):100737","journal-title":"Ann Hepatol"},{"issue":"10","key":"5875_CR8","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1007\/s00432-016-2218-0","volume":"142","author":"T Gao","year":"2016","unstructured":"Gao T et al (2016) DCLK1 is up-regulated and associated with metastasis and prognosis in colorectal cancer. J Cancer Res Clin Oncol 142(10):2131\u20132140","journal-title":"J Cancer Res Clin Oncol"},{"issue":"5","key":"5875_CR9","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1002\/ijc.31400","volume":"143","author":"Y Ge","year":"2018","unstructured":"Ge Y et al (2018) Alternative splice variants of DCLK1 mark cancer stem cells, promote self-renewal and drug-resistance, and can be targeted to inhibit tumorigenesis in kidney cancer. Int J Cancer 143(5):1162\u20131175","journal-title":"Int J Cancer"},{"issue":"12","key":"5875_CR10","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1158\/1541-7786.MCR-21-0161","volume":"19","author":"Y Ge","year":"2021","unstructured":"Ge Y et al (2021) DCLK1-short splice variant promotes esophageal squamous cell carcinoma progression via the MAPK\/ERK\/MMP2 pathway. Mol Cancer Res 19(12):1980\u20131991","journal-title":"Mol Cancer Res"},{"key":"5875_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01827-6","author":"A Glaviano","year":"2023","unstructured":"Glaviano A et al (2023) PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer. Mol Cancer. https:\/\/doi.org\/10.1186\/s12943-023-01827-6","journal-title":"Mol Cancer"},{"issue":"6","key":"5875_CR12","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41575-022-00741-4","volume":"20","author":"TF Greten","year":"2023","unstructured":"Greten TF et al (2023) Immunology and immunotherapy of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol 20(6):349\u2013365","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"5875_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00828-5","author":"Y He","year":"2021","unstructured":"He Y et al (2021) Targeting PI3K\/Akt signal transduction for cancer therapy. Signal Trans Targeted Ther. https:\/\/doi.org\/10.1038\/s41392-021-00828-5","journal-title":"Signal Trans Targeted Ther."},{"issue":"6","key":"5875_CR14","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1158\/1541-7786.MCR-16-0285","volume":"15","author":"Y Ikezono","year":"2017","unstructured":"Ikezono Y et al (2017) Pancreatic neuroendocrine tumors and emt behavior are driven by the CSC marker DCLK1. Mol Cancer Res 15(6):744\u2013752","journal-title":"Mol Cancer Res"},{"key":"5875_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-022-02632-9","author":"E Kalantari","year":"2022","unstructured":"Kalantari E et al (2022) Oncogenic functions and clinical significances of DCLK1 isoforms in colorectal cancer: a systematic review and meta-analysis. Cancer Cell Int. https:\/\/doi.org\/10.1186\/s12935-022-02632-9","journal-title":"Cancer Cell Int"},{"issue":"S1","key":"5875_CR16","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/liv.14093","volume":"39","author":"T Kendall","year":"2019","unstructured":"Kendall T et al (2019) Anatomical, histomorphological and molecular classification of cholangiocarcinoma. Liver Int 39(S1):7\u201318","journal-title":"Liver Int"},{"key":"5875_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5391-0","author":"PL Labib","year":"2019","unstructured":"Labib PL, Goodchild G, Pereira SP (2019) Molecular pathogenesis of cholangiocarcinoma. BMC Cancer. https:\/\/doi.org\/10.1186\/s12885-019-5391-0","journal-title":"BMC Cancer"},{"key":"5875_CR18","unstructured":"Li L, Bellows CF (2013) Doublecortin-like kinase 1 exhibits cancer stem cell-like characteristics in a human colon cancer cell line. \u4e2d\u56fd\u764c\u75c7\u7814\u7a76: \u82f1\u6587\u7248 2013(2): 9"},{"issue":"1","key":"5875_CR19","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1159\/000495228","volume":"51","author":"J Li","year":"2018","unstructured":"Li J et al (2018) Doublecortin-like kinase 1 (DCLK1) regulates B cell-specific moloney murine leukemia virus insertion site 1 (Bmi-1) and is associated with metastasis and prognosis in pancreatic cancer. Cell Physiol Biochem 51(1):262\u2013277","journal-title":"Cell Physiol Biochem"},{"key":"5875_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-023-01642-3","author":"H Liu","year":"2023","unstructured":"Liu H et al (2023) Targeting DCLK1 attenuates tumor stemness and evokes antitumor immunity in triple-negative breast cancer by inhibiting IL-6\/STAT3 signaling. Breast Cancer Res. https:\/\/doi.org\/10.1186\/s13058-023-01642-3","journal-title":"Breast Cancer Res"},{"issue":"2","key":"5875_CR21","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.jhep.2019.11.020","volume":"72","author":"V Mazzaferro","year":"2020","unstructured":"Mazzaferro V et al (2020) Liver resection and transplantation for intrahepatic cholangiocarcinoma. J Hepatol 72(2):364\u2013377","journal-title":"J Hepatol"},{"issue":"1","key":"5875_CR22","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/hep.31630","volume":"73","author":"V Meadows","year":"2021","unstructured":"Meadows V, Francis H (2021) Doublecortin-like kinase protein 1 in cholangiocarcinoma: is this the biomarker and target we have been looking for? Hepatology 73(1):4\u20136","journal-title":"Hepatology"},{"issue":"1","key":"5875_CR23","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1002\/hep.31571","volume":"73","author":"L Nevi","year":"2021","unstructured":"Nevi L et al (2021) DCLK1, a putative stem cell marker in human cholangiocarcinoma. Hepatology 73(1):144\u2013159","journal-title":"Hepatology"},{"key":"5875_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605779","author":"D-Y Oh","year":"2022","unstructured":"Oh D-Y et al (2022) Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid. https:\/\/doi.org\/10.1038\/sj.bjc.6605779","journal-title":"NEJM Evid"},{"issue":"4","key":"5875_CR25","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/sj.bjc.6605779","volume":"103","author":"T Okusaka","year":"2010","unstructured":"Okusaka T et al (2010) Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer 103(4):469\u2013474","journal-title":"Br J Cancer"},{"issue":"3","key":"5875_CR26","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s100380050063","volume":"43","author":"Y Omori","year":"1998","unstructured":"Omori Y et al (1998) Expression and chromosomal localization of KIAA0369, a putative kinase structurally related to Doublecortin. J Hum Genet 43(3):169\u2013177","journal-title":"J Hum Genet"},{"issue":"9","key":"5875_CR27","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1016\/j.str.2016.07.008","volume":"24","author":"O Patel","year":"2016","unstructured":"Patel O et al (2016) Biochemical and structural insights into doublecortin-like kinase domain 1. Structure 24(9):1550\u20131561","journal-title":"Structure"},{"issue":"12","key":"5875_CR28","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1093\/annonc\/mdu456","volume":"25","author":"M Piccart","year":"2014","unstructured":"Piccart M et al (2014) Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2. Ann Oncol 25(12):2357\u20132362","journal-title":"Ann Oncol"},{"key":"5875_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2019\/6402925","volume":"2019","author":"D Qu","year":"2019","unstructured":"Qu D et al (2019) Overexpression of DCLK1-AL increases tumor cell invasion, drug resistance, and KRAS activation and can be targeted to inhibit tumorigenesis in pancreatic cancer. J Oncol 2019:1\u201311","journal-title":"J Oncol"},{"issue":"6","key":"5875_CR30","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1053\/j.gastro.2013.10.013","volume":"145","author":"S Rizvi","year":"2013","unstructured":"Rizvi S, Gores GJ (2013) Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology 145(6):1215\u20131229","journal-title":"Gastroenterology"},{"issue":"2","key":"5875_CR31","first-page":"95","volume":"15","author":"S Rizvi","year":"2017","unstructured":"Rizvi S et al (2017) Cholangiocarcinoma\u2014evolving concepts and therapeutic strategies. Nat Rev Clin Oncol 15(2):95\u2013111","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"5875_CR32","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s12029-021-00728-5","volume":"54","author":"R Sahu","year":"2022","unstructured":"Sahu R, Sharma P, Kumar A (2022) An insight into cholangiocarcinoma and recent advances in its treatment. J Gastrointest Cancer 54(1):213\u2013226","journal-title":"J Gastrointest Cancer"},{"issue":"3","key":"5875_CR33","doi-asserted-by":"publisher","first-page":"158","DOI":"10.32074\/1591-951X-252","volume":"113","author":"S Sarcognato","year":"2021","unstructured":"Sarcognato S et al (2021) Cholangiocarcinoma. Pathologica 113(3):158\u2013169","journal-title":"Pathologica"},{"key":"5875_CR34","doi-asserted-by":"crossref","unstructured":"Siegel RL, et al (2023) Cancer statistics, 2023. CA: A Cancer J Clin 73(1): 17\u201348","DOI":"10.3322\/caac.21763"},{"key":"5875_CR35","doi-asserted-by":"publisher","first-page":"51","DOI":"10.21037\/sci.2016.09.07","volume":"3","author":"P Singh","year":"2016","unstructured":"Singh P, O\u2019Connell M, Shubhashish S (2016) Epigenetic regulation of human DCLK-1 gene during colon-carcinogenesis: clinical and mechanistic implications. Stem Cell Investig 3:51\u201351","journal-title":"Stem Cell Investig"},{"issue":"10295","key":"5875_CR36","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S0140-6736(21)00580-8","volume":"398","author":"C Sweeney","year":"2021","unstructured":"Sweeney C et al (2021) Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial. The Lancet 398(10295):131\u2013142","journal-title":"The Lancet"},{"key":"5875_CR37","first-page":"1273","volume":"14","author":"JI Valle","year":"2010","unstructured":"Valle JI et al (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. Massachusetts Med Soc 14:1273","journal-title":"Massachusetts Med Soc"},{"issue":"6","key":"5875_CR38","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1016\/j.jhep.2022.07.022","volume":"77","author":"M Vithayathil","year":"2022","unstructured":"Vithayathil M, Khan SA (2022) Current epidemiology of cholangiocarcinoma in Western countries. J Hepatol 77(6):1690\u20131698","journal-title":"J Hepatol"},{"issue":"2","key":"5875_CR39","doi-asserted-by":"publisher","first-page":"274","DOI":"10.3390\/cancers12020274","volume":"12","author":"X Wu","year":"2020","unstructured":"Wu X et al (2020) Cancer stem cell marker DCLK1 correlates with tumorigenic immune infiltrates in the colon and gastric adenocarcinoma microenvironments. Cancers 12(2):274","journal-title":"Cancers"},{"key":"5875_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2019.117150","volume":"241","author":"R Yan","year":"2020","unstructured":"Yan R et al (2020) Inhibition of DCLK1 down-regulates PD-L1 expression through Hippo pathway in human pancreatic cancer. Life Sci 241:117150","journal-title":"Life Sci"},{"key":"5875_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.tice.2023.102163","volume":"84","author":"K Yasodha","year":"2023","unstructured":"Yasodha K et al (2023) Exosomes from metastatic colon cancer cells drive the proliferation and migration of primary colon cancer through increased expression of cancer stem cell markers CD133 and DCLK1. Tissue Cell 84:102163","journal-title":"Tissue Cell"},{"key":"5875_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2023.122294","volume":"336","author":"L Ye","year":"2024","unstructured":"Ye L et al (2024) DCLK1 and its oncogenic functions: a promising therapeutic target for cancers. Life Sci 336:122294","journal-title":"Life Sci"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-024-05875-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-024-05875-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-024-05875-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T17:08:49Z","timestamp":1723050529000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-024-05875-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,9]]},"references-count":42,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["5875"],"URL":"https:\/\/doi.org\/10.1007\/s00432-024-05875-3","relation":{},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,9]]},"assertion":[{"value":"23 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors declare no potential conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All experiments included in this research obtained ethical approval by the ethics committee of Beijing Chaoyang Hospital, Capital Medical University. All animal experiments in this research were approved by the Institutional Animal Care and Use committee of Capital Medical University.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}},{"value":"If not applicable, please write N\/A. Registry and the Registration No. of the study\/trial. If not applicable, please write N\/A.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"342"}}